[October 02, 2015]

Research and Markets: Marburg Hemorrhagic Fever Pipeline Review, H2 2015 - 6 Companies & 7 Drug Profiles

Research and Markets (http://www.researchandmarkets.com/research/8n7x8l/marburg) has announced the addition of the "Marburg Hemorrhagic Fever - Pipeline Review, H2 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Marburg Hemorrhagic Fever, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development fr Marburg Hemorrhagic Fever and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Involved in Therapeutics Development

• Arbutus Biopharma Corporation
• Crucell N.V.
• GlaxoSmithKline Plc
• Immunovaccine, Inc.
• Integrated BioTherapeutics, Inc.
• Sarepta Therapeutics, Inc.

Drug Profiles

• AVI-7288
• ebola [strain sudan, zaire] + marburg vaccine
• marburg vaccine
• Monoclonal Antibodies for Ebola and Marburg Infections
• Monoclonal Antibody for Marburg Virus
• panfilovirus (multivalent) vaccine
• TKM-Marburg

For more information visit http://www.researchandmarkets.com/research/8n7x8l/marburg

View source version on businesswire.com: http://www.businesswire.com/news/home/20151002005343/en/

[ Back To TMCnet.com's Homepage ]